GLP-1 Bridge Program Offers Medicare Beneficiaries New Access to Obesity Drugs
The Centers for Medicare & Medicaid Services (CMS) has launched the GLP-1 Bridge program, designed to provide Medicare beneficiaries access to obesity medications that were previously uncovered. This initiative operates under the federal government's Section 402 demonstration authority, aiming to offer these drugs for weight loss purposes. Running until December 31, 2027, the pilot makes GLP-1 medications available to eligible Medicare Part D recipients at a reduced monthly cost of $50.
CMS Administrator Dr. Mehmet Oz emphasized that the Bridge program opens a new pathway to affordability for GLP-1 medications, which cost constraints have kept out of reach for many beneficiaries. Nonetheless, industry voices like Dared Price, President of Price Pharmacies Inc., express concern regarding the potential financial strain on the Medicare system due to high anticipated demand.
Estimates suggest around 3.8 million Medicare beneficiaries might join the program, with monthly costs potentially escalating to $741 million if all eligible individuals enroll. Manufacturers have agreed to a net price of $245 per month for GLP-1 medications, alleviating the financial burden on beneficiaries through discounted copays.
Currently, only a minority of employers provide coverage for GLP-1 medications for both diabetes and weight loss, with many insurers limiting approval to glucose management. States like California, Pennsylvania, and South Carolina have also amended their Medicaid program offerings to reflect these constraints.
Pharmacies face operational challenges with the Bridge program's rollout, including plan identification issues for prescription processing and eligibility confirmation, which may cause delays. Medical experts emphasize the risk of misuse if not paired with comprehensive support, underscoring the need for holistic treatment plans.
Stakeholders, such as Millicent Gorham, CEO of the Alliance for Women’s Health and Prevention, call for expanded coverage that includes diverse treatment options to ensure long-term sustainability in obesity management. Legislative interest, including the proposed Treat and Reduce Obesity Act, indicates evolving policy dynamics in this realm.
The GLP-1 Bridge program's introduction presents both challenges and opportunities in evolving the obesity treatment framework within Medicare. Its impact on beneficiaries and the overall Medicare system will unfold amid ongoing policy discussions and potential legislative changes.